长春瑞宾联合顺铂治疗非小细胞肺癌的疗效及预后的多因素分析

目的探讨长春瑞宾(NVB)联合顺铂(PDD)治疗非小细胞肺癌患者影响疗效、预后的因素.方法分别选择临床病理因素,应用Logistic回归及Cox比例风险模型对影响疗效、预后的因素进行分析.结果全组总有效率(RR)为30.2 %(62/205),其中初治为32.0%(48/150),复治为26.5%(14/55),中位生存期8.3个月,1年生存率为37.81%,2年生存率为15.44%,3年生存率为5.39%.多因素分析显示,女性、肺鳞癌及治疗前一般状况较好者有较好的疗效(P<0.05);治疗前体重丢失情况与完成治疗的周期数(P<0.0005)为影响预后因素,肺腺癌患者在本组获得较长生存期.结论 NVB联合顺铂是治疗非小细胞肺癌较好的方案,影响疗效重要因素为性别、病理类型及一般状况.本组影响预后因素为治疗前体重丢失情况、完成治疗的周期数,肺腺癌在本组获得较长生存期.

Multi-factorial analysis of the effect and the prognosis of Vinorelbine and Cisplatin combination chemotherapy in the treatment of non-small cell lung cancer

Objective To analyze the effect, prognosis and related factors of Vinorelbine and Cisplatin combined chemotherapy in the treatment of non small cell lung cancer.Methods 205 cases who received Vinorelbine and Cisplatin combined chemotherapy were enrolled into the study.Logistic regression and Cox proportional hazard model were used to perform multivariable analysis with the clinic factors which might affect the effect and prognosis.Results A total response rate (CR PR) was observed in 30.2%(62/205),initial treatment response and retreatment response was observed in 32%(48/150) and 26.5%(14/55).The median survival time was 8 months.Survival at one year, two year and three year represented 37.81%,15.44% and 5.39% respectively.The multivariate analysis showed female( P =0.003),squamous carcinoma and better performance status( P <0.05)were effect influencing factors.Weight loss,number of treating courses were the prognosis influencing factors ( P <0.0005).Adenocarcinoma had better long term survival.Conclusions Vinorelbine plus Cisplatin combination chemotherapy is a better regimen in the treatment of non small cell lung cancer.The main factors that influence the efficacy were gender,pathological type,and performance status;while pathological type,performance status,weight loss,and number of treating courses were prognosis influencing factors.Patients with adenocarcinoma has better long term survival rate.